Hormones and venous thromboembolism among postmenopausal women

Climacteric

Volumn 17, Issue , 2014, Pages 34-37

  Scarabin, P Y ^a  

^a INSERM   (France)

Author keywords

Estrogens; Hemostasis; Postmenopausal Hormone Therapy; Progestogen; Venous Thromboembolism

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE; PROGESTERONE;

CONFERENCE PAPER; GENETICS; HEMOSTASIS; HORMONAL THERAPY; HUMAN; OBESITY; POSTMENOPAUSE; PRACTICE GUIDELINE; THROMBOSIS; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPLICATION; ESTROGEN THERAPY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK FACTOR;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; OBESITY; POSTMENOPAUSE; PROGESTERONE; PROGESTINS; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 84911399580     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.956717     Document Type: Conference Paper

References (21)

1. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64
2. Scarabin P Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res 2014;43:21-32
3. Scarabin PY, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32
4. Canonico M, O ger E, P lu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5
5. Canonico M, F ournier A, Carcaillon L, et al. P ostmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5
6. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemost 2010;8:979-86
7. Sweetland S, Beral V, Balkwill A, et al.; The Million Women Study Collaborators. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost 2012;10:2277-86
8. Roach RE, Lijfering WM, Helmerhorst FM, et al. The risk of venous thrombosis in womeNover 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost 2013;11:124-31
9. De Lignieres B, Basdevant A, T homas G, et al. B iological effects of estradiol-17 βin postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 1986;62:536-41
10. Scarabin PY, A lhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fi brinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997;17:3071-8
11. Oger E, Alhenc-Gelas M, Lacut K, et al. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23:1671-6
12. Smith N L, B london M, W iggins K L, et al. L ower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugatedequine estrogens. JAMA Intern Med 2014;174:25-31
13. Stanczyk F Z, H apgood J P, W iner S, M ishell D R J r. P rogestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013;34:171-208
14. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention andextended poststopping phases of theWomen's Health Initiative randomized trials. JAMA 2013;310:1353-68
15. Vickers MR, MacLennan AH, Lawton B, et al. Main morbidities recorded in the Women's International Study of Long Duration oestrogen after Menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239
16. Morange P E, T ré gou ë t D A. C urrent knowledge on thEgenetics of incident venous thrombosis. J Thromb Haemost 2013;11(Suppl 1):111-21
17. Canonico M, B ouaziz E, Carcaillon L, et al. S ynergism betweeNoral estrogen therapy and cytochrome P450 3A5 ∗ 1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082-7
18. Blondon M, Wiggins KL, Harrington LB, Psaty BM, S mith NL. Lack of strong effect modifi cation by NFE2L2/CYP3A5/ABO of the risk of venous thrombosis associated with oral hormone therapy. J Thromb Haemost 2013;11:1617-19
19. Rossouw J, Bray P, L iu J, et al. E strogen receptor polymorphisms and the vascular effects of hormone therapy. Arterioscler Thromb Vasc Biol 2011;31:464-9
20. Tremollieres F, Brincat M, Erel CT, et al.; European Menopause and Andropause Society. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas 2011;69:195-8
21. de Villiers T J, P ines A, P anay N, et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316-37